Last reviewed · How we verify

Vincristine, Carboplatin and Etoposide

St. Jude Children's Research Hospital · Phase 3 active Small molecule

Vincristine, Carboplatin and Etoposide is a Combination chemotherapy (vinca alkaloid + platinum agent + topoisomerase II inhibitor) Small molecule drug developed by St. Jude Children's Research Hospital. It is currently in Phase 3 development for Pediatric cancers (likely lymphomas, leukemias, or solid tumors based on St. Jude focus). Also known as: Onconvin and Paraplatin and Vepesid.

This combination chemotherapy regimen kills cancer cells by disrupting microtubule formation (vincristine), damaging DNA (carboplatin), and inhibiting topoisomerase II (etoposide).

This combination chemotherapy regimen kills cancer cells by disrupting microtubule formation (vincristine), damaging DNA (carboplatin), and inhibiting topoisomerase II (etoposide). Used for Pediatric cancers (likely lymphomas, leukemias, or solid tumors based on St. Jude focus).

At a glance

Generic nameVincristine, Carboplatin and Etoposide
Also known asOnconvin and Paraplatin and Vepesid
SponsorSt. Jude Children's Research Hospital
Drug classCombination chemotherapy (vinca alkaloid + platinum agent + topoisomerase II inhibitor)
TargetTubulin (vincristine), DNA (carboplatin), Topoisomerase II (etoposide)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Vincristine is a vinca alkaloid that binds tubulin and prevents microtubule assembly, arresting cells in metaphase. Carboplatin is a platinum-based agent that forms DNA crosslinks, causing strand breaks and cell death. Etoposide is a topoisomerase II inhibitor that prevents DNA religation, leading to double-strand breaks. Together, these agents provide synergistic cytotoxic activity against rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vincristine, Carboplatin and Etoposide

What is Vincristine, Carboplatin and Etoposide?

Vincristine, Carboplatin and Etoposide is a Combination chemotherapy (vinca alkaloid + platinum agent + topoisomerase II inhibitor) drug developed by St. Jude Children's Research Hospital, indicated for Pediatric cancers (likely lymphomas, leukemias, or solid tumors based on St. Jude focus).

How does Vincristine, Carboplatin and Etoposide work?

This combination chemotherapy regimen kills cancer cells by disrupting microtubule formation (vincristine), damaging DNA (carboplatin), and inhibiting topoisomerase II (etoposide).

What is Vincristine, Carboplatin and Etoposide used for?

Vincristine, Carboplatin and Etoposide is indicated for Pediatric cancers (likely lymphomas, leukemias, or solid tumors based on St. Jude focus).

Who makes Vincristine, Carboplatin and Etoposide?

Vincristine, Carboplatin and Etoposide is developed by St. Jude Children's Research Hospital (see full St. Jude Children's Research Hospital pipeline at /company/st-jude-children-s-research-hospital).

Is Vincristine, Carboplatin and Etoposide also known as anything else?

Vincristine, Carboplatin and Etoposide is also known as Onconvin and Paraplatin and Vepesid.

What drug class is Vincristine, Carboplatin and Etoposide in?

Vincristine, Carboplatin and Etoposide belongs to the Combination chemotherapy (vinca alkaloid + platinum agent + topoisomerase II inhibitor) class. See all Combination chemotherapy (vinca alkaloid + platinum agent + topoisomerase II inhibitor) drugs at /class/combination-chemotherapy-vinca-alkaloid-platinum-agent-topoisomerase-ii-inhibitor.

What development phase is Vincristine, Carboplatin and Etoposide in?

Vincristine, Carboplatin and Etoposide is in Phase 3.

What are the side effects of Vincristine, Carboplatin and Etoposide?

Common side effects of Vincristine, Carboplatin and Etoposide include Myelosuppression (neutropenia, thrombocytopenia, anemia), Nausea and vomiting, Peripheral neuropathy, Alopecia, Mucositis, Infection.

What does Vincristine, Carboplatin and Etoposide target?

Vincristine, Carboplatin and Etoposide targets Tubulin (vincristine), DNA (carboplatin), Topoisomerase II (etoposide) and is a Combination chemotherapy (vinca alkaloid + platinum agent + topoisomerase II inhibitor).

Related